{"id":"npc-09","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Genital amputations"},{"rate":"null","effect":"Increased risk of acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL2372276","moleculeType":"Protein","molecularWeight":"1363.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NPC-09 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"NPC-09 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:24.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04671472","phase":"PHASE3","title":"Efficacy Confirmation Study of NPC-09","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2021-02-08","conditions":"GNE Myopathy, Distal Myopathy With Rimmed Vacuoles (DMRV), Hereditary Inclusion Body Myopathy (hIBM)","enrollment":14},{"nctId":"NCT01236898","phase":"PHASE1","title":"Pharmacokinetic Study on N-acetylneuraminic Acid","status":"COMPLETED","sponsor":"Tohoku University","startDate":"2010-11","conditions":"Nonaka Myopathy, Hereditary Inclusion Body Myopathy","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aceneuramic acid tablets","Aceneuramic acid matching placebo"],"phase":"phase_3","status":"active","brandName":"NPC-09","genericName":"NPC-09","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPC-09 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}